GLUE vs. NRIX, KNSA, RCUS, OCUL, MRVI, ARVN, PRAX, CALT, DAWN, and ANIP
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Maravai LifeSciences (MRVI), Arvinas (ARVN), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
Monte Rosa Therapeutics vs.
Monte Rosa Therapeutics (NASDAQ:GLUE) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.
In the previous week, Nurix Therapeutics had 5 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 7 mentions for Nurix Therapeutics and 2 mentions for Monte Rosa Therapeutics. Nurix Therapeutics' average media sentiment score of 0.23 beat Monte Rosa Therapeutics' score of 0.22 indicating that Nurix Therapeutics is being referred to more favorably in the news media.
Monte Rosa Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 147.35%. Nurix Therapeutics has a consensus target price of $30.35, indicating a potential upside of 58.58%. Given Monte Rosa Therapeutics' higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Nurix Therapeutics.
Nurix Therapeutics received 61 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 78.95% of users gave Nurix Therapeutics an outperform vote while only 46.67% of users gave Monte Rosa Therapeutics an outperform vote.
Monte Rosa Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -313.65%. Monte Rosa Therapeutics' return on equity of -62.68% beat Nurix Therapeutics' return on equity.
Monte Rosa Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500.
Summary
Nurix Therapeutics beats Monte Rosa Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GLUE) was last updated on 1/18/2025 by MarketBeat.com Staff
Free GLUE Stock Alerts